← Leaderboards
Leslie Z Benet
University Of California San Francisco
$3,583,449
Attributed
$3,915,622
Total exposure
15
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $439.3K · FY2005–15$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$3,915,622 · 15
By mechanism
R21$1,085,297 · 1
R01$796,526 · 2
M01$727,300 · 6
R43$664,346 · 2
P01$622,393 · 2
P41$19,760 · 2
Top collaborators
- Yong Huang1 shared
- Mark S. Warren1 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Kathleen M Giacomini$35,943,104
- June H Lee$7,095,874
- Donald I Abrams$10,076,278
- John E Conte$521,293
Others in their field
Top investigators on “Pharmacokinetics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$237,100,725
- Constance Ann Benson · University Of California, San Diego$151,891,628
- Richard L Schilsky · University Of Chicago$114,474,127
- Ronald T Mitsuyasu · University Of California Los Angeles$105,970,100
- Wafaa M. El-Sadr · Columbia University Health Sciences$91,574,471
- Myron S Cohen · Family Health International$91,263,426
Research focus
PharmacokineticsHuman SubjectClinical ResearchP GlycoproteinDrug InteractionsGastrointestinal Drug AbsorptionDigoxinEnzyme InhibitorsCytochrome P450Clinical Trial Phase ILiverDrug MetabolismEnzymesSpectrometryStructural BiologyBiological ProductsDrug Adverse EffectIntestinesTransplantationBiomedical ResourceHuman TissueGene ExpressionFemaleFk506
Grant awards (40)
A novel mechanistic modeling platform for predicting drug clearance and disposition mediated by transporters and enzymes$225,000
R43 · FY2015 · GM
A Transporter-Based Predictive ADME Platform$439,346
R43 · FY2010 · RR
Transporter-Enzyme Interplay Evaluation via Microfluidiic HTS Cell Culture Device$354,877
R21 · FY2008 · GM · contact PI
Transporter-Enzyme Interplay Evaluation via Microfluidiic HTS Cell Culture Device$360,579
R21 · FY2007 · GM · contact PI
Transporter-Enzyme Interplay Evaluation via Microfluidiic HTS Cell Culture Device$369,841
R21 · FY2006 · GM · contact PI
UREMIC TOXINS AND ERYTHROMYCIN METABOLISM$50,973
M01 · FY2005 · RR
P-Gp Expression and Function in Treatment of HIV+ Women$121,219
M01 · FY2004 · RR
Cyclosporine in Diabetic Renal Transplantation$5,780
M01 · FY2004 · RR
ACYLCOA FORMATION--COVALENT BINDING, PHARMACOKINETICS$264,637
R01 · FY2002 · GM
P-GLYCOPROTEIN EXPRESSION AND FUNCTION IN HIV+ WOMEN$205,924
P01 · FY2002 · HD
P-GLYCOPROTEIN EXPRESSION AND FUNCTION IN HIV+ WOMEN$205,924
P01 · FY2002 · HD
EFFECTS OF FLUCONAZOLE ON PHARMACOKINETICS OF TACROLIMUS$68,666
M01 · FY2002 · RR
EFFECT OF INTESTINAL TRANSPORTERS ON BIOAVAILABILITY OF DIURETIC FUROSEMIDE$68,666
M01 · FY2002 · RR
Pharmacokinetic interactions: digoxin /grapefruit juice$68,666
M01 · FY2002 · RR
EFFECTS OF ITRACONAZOLE &KETOCONAZOLE ON DIGOXIN PHARMACOKINETICS$68,666
M01 · FY2002 · RR
BIOTRANSFORMATION OF FK506$0
P41 · FY2002 · RR
CORE--PHARMACOKINETICS/PHARMACODYNAMICS$0
P01 · FY2002 · CA
EXPLORATION OF ALBUMIN AS MODEL FOR MEASUREMENT OF XENOBIOTIC EXPOSURE IN HUMANS$0
P41 · FY2002 · RR
ACYLCOA FORMATION--COVALENT BINDING, PHARMACOKINETICS$258,153
R01 · FY2001 · GM
EFFECT OF INTESTINAL TRANSPORTERS ON BIOAVAILABILITY OF DIURETIC FUROSEMIDE$68,666
M01 · FY2001 · RR
EFFECTS OF ITRACONAZOLE &KETOCONAZOLE ON DIGOXIN PHARMACOKINETICS$68,666
M01 · FY2001 · RR
EFFECTS OF FLUCONAZOLE ON PHARMACOKINETICS OF TACROLIMUS$68,666
M01 · FY2001 · RR
Pharmacokinetic interactions: digoxin /grapefruit juice$68,666
M01 · FY2001 · RR
EXPLORATION OF ALBUMIN AS MODEL FOR MEASUREMENT OF XENOBIOTIC EXPOSURE IN HUMANS$0
P41 · FY2001 · RR
EFFECTS OF FLUCONAZOLE ON PHARMACOKINETICS OF TACROLIMUS$0
M01 · FY2001 · RR
EFFECTS OF ITRACONAZOLE &KETOCONAZOLE ON DIGOXIN PHARMACOKINETICS$0
M01 · FY2001 · RR
EFFECT OF INTESTINAL TRANSPORTERS ON BIOAVAILABILITY OF DIURETIC FUROSEMIDE$0
M01 · FY2001 · RR
Pharmacokinetic interactions: digoxin /grapefruit juice$0
M01 · FY2001 · RR
CORE--PHARMACOKINETICS/PHARMACODYNAMICS$0
P01 · FY2001 · CA
P-GLYCOPROTEIN EXPRESSION AND FUNCTION IN HIV+ WOMEN$0
P01 · FY2001 · HD
BIOTRANSFORMATION OF FK506$0
P41 · FY2001 · RR
ACYLCOA FORMATION--COVALENT BINDING, PHARMACOKINETICS$251,669
R01 · FY2000 · GM
CORE--PHARMACOKINETICS/PHARMACODYNAMICS$210,545
P01 · FY2000 · CA
IMMUNOPHARMACOKINETICS AND IMMUNOPHARMACODYNAMICS$22,067
R01 · FY2000 · GM
EXPLORATION OF ALBUMIN AS MODEL FOR MEASUREMENT OF XENOBIOTIC EXPOSURE IN HUMANS$9,880
P41 · FY2000 · RR
BIOTRANSFORMATION OF FK506$9,880
P41 · FY2000 · RR
EFFECTS OF ITRACONAZOLE &KETOCONAZOLE ON DIGOXIN PHARMACOKINETICS$0
M01 · FY2000 · RR
Pharmacokinetic interactions: digoxin /grapefruit juice$0
M01 · FY2000 · RR
EFFECT OF INTESTINAL TRANSPORTERS ON BIOAVAILABILITY OF DIURETIC FUROSEMIDE$0
M01 · FY2000 · RR
EFFECTS OF FLUCONAZOLE ON PHARMACOKINETICS OF TACROLIMUS$0
M01 · FY2000 · RR